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Based on the strong evidences between inflammation and neurodegeneration, nonsteroidal anti-inflammatory drugs (NSAIDs),
such as ibuprofen, are considered as effective agents to reduce the risk of Alzheimer’s and Parkinson’s disease. However, the clinical
use of NSAIDs in these diseases is limited by low brain distribution. In this study, we had synthesized ibuprofen conjugate which
has good brain penetration. S-(+)-Ibuprofen was covalently attached to a molecular transporter having FITC and eight terminal
guanidine groups. This conjugate showed good cellular uptake property in live cells. It was also injected into a mouse and the
distribution of the compoundwas examined in each organ.The conjugatewaswell delivered tomouse brain indicating the conjugate
is able to cross the blood-brain barrier. Our novel synthetic ibuprofen conjugate will hopefully deliver other NSAIDs into brain and
is therefore applicable to the neurodegenerative diseases treatment or prevention.
1. Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are effec-
tive for relieving pain and reducing inflammation. These are
nonselective inhibitors of two isoforms of cyclooxygenase
(COX), cyclooxygenase-1 (COX-1) and cyclooxygenase-2
(COX-2), and thereby inhibit the production of hormone-like
lipid compounds such as prostaglandins and thromboxane
which cause inflammation, pain, fever, and platelet aggre-
gation [1, 2]. Approximately 33 million Americans annually
use these compounds for the symptomatic relief of headache,
osteoarthritis, rheumatoid arthritis, low back pain, and mus-
culoskeletal conditions. Moreover, many epidemiological
studies demonstrate that NSAIDs have a neuroprotective
effect against neurodegenerative diseases, such asAlzheimer’s
disease and Parkinson’s disease [3–7]. Brain response to
cellular stress, injury, and pathology can lead to neuroin-
flammation which upregulatesmicroglia cells.The aberrantly
activated microglia could induce chronic inflammation and
cellular damage by producing diverse cytokines and reac-
tive oxygen species (ROS), accelerating neuronal death and
resulting in neurodegenerative disease [8–10]. Since NSAIDs
can reduce inflammation in brain and allow beneficial effects
on preventing or reducing neurodegenerative diseases, along
with the principal therapeutic effect (e.g., anti-inflammation)
of NSAID, herein we would focus on its neuroprotective
effects.
Ibuprofen is a propionic acid derivative among NSAID
classes and was the first nonaspirin NSAID to be available
over the counter and has become the most commonly used
NSAID. Recently, it is reported that long term oral admin-
istration of ibuprofen could delay the onset of Alzheimer’s,
as is found with other NSAIDs [11, 12]. When ibuprofen was
fed to transgenic mice models for Alzheimer’s, both central
nervous system (CNS) inflammation and Alzheimer plaque
deposition in the brain were significantly reduced [11]. In
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Figure 1: The presence of BBB prevents the ibuprofen internaliza-
tion into the brain. Our objective is to make ibuprofen conjugate
pass through the BBB.
clinical research, data from almost 250,000 cases showed
those who took NSAID for more than five years were more
than 40% less likely to develop Alzheimer’s [12]. The study
also revealed that, among the NSAIDs taken by patients,
ibuprofen showed the most profound effect. Furthermore, a
study suggests taking ibuprofen regularly to be also associated
with lowering the risk of the development of Parkinson’s
disease [13]. The study reported that those taking ibuprofen
regularly more than six years showed a 38% lower risk of
developing the disorder than nonusers and other NSAIDs,
such as aspirin and paracetamol, did not show any effect to
the patients.
However, there are many challenges to be overcome for
ibuprofen and other NSAIDs to be used as treatments for
neural disorders. First, the presence of blood-brain barrier
(BBB) has been reported to significantly limit the brain
penetration of NSAIDs (Figure 1) [14–17]. The BBB between
cerebral blood and the interstitial fluid of the brain acts
as protection from an influx of pathogens as well as small
useful molecular drugs like NSAIDs. In addition, ibuprofen
is ionized at physiological pH and circulates as anions, which
are extensively bound to plasma proteins by noncovalent
associations [18, 19]. As a consequence, brain penetration of
ibuprofen was found to be low in rats, showing the total brain
to plasma ratio being less than 0.02. Therefore, ibuprofen
reaching the human brain exists in only a tiny amount and
high doses might be required to attain a certain level of
drug efficacy toward neural disorders. Also, long term use
of ibuprofen can cause a number of side-effects, such as
cardiovascular and gastrointestinal risks.
Therefore, to make ibuprofen a more potent drug to
prevent or alleviate neurodegenerative diseases even in low
doses, delivery of ibuprofen to brain should be effective and
ibuprofen must penetrate the BBB and gain access into the
patient’s brain.
We have recently developed several types of guanidine-
richmolecular carrierswith highmolecularweights and good
water solubility that readily cross the BBB anddisplay efficient
distributions in themouse brain [20, 21]. In particular, the G8
(having eight guanidine groups) molecular carrier based on
carbohydrate, such as sorbitol, was found to be very effective
in delivering conjugated drugs to mouse brain [22–25]. In
the present study, employing the same molecular carrier,
we prepared the ibuprofen conjugate and studied its BBB
permeability by mouse tissue distribution study.
2. Experimental
2.1. Materials and Methods in Synthesis. Analytical TLC
was performed on Merck 60 F254 silica gel plate (0.25mm
thickness) and visualized under UV light and/or by spraying
with a 5% solution of phosphomolybdic acid (PMA) in
ethanol or ninhydrin specific for amino compounds, followed
by charring with a heat gun. Column chromatography was
performed on Merck 60 silica gel (70–230 or 230–400mesh)
and MPLC on Fluka 100 C8-reversed phase silica gel. NMR
spectra were recorded on a Bruker ASPECT 300 instrument
operating at 300MHz for 1H, 75MHz for 13C. Chemical
shifts were reported in parts per million (ppm) relative to
tetramethylsilane (TMS) or deuterium oxide (D2O) which
were used as internal and external standard for the 1HNMR.
Mass spectra were recorded on fast atom bombardment
(FAB) conditions. In case of highmass spectral data,MALDI-
TOF were obtained on a Micromass M@DI at the Biomolec-
ular Diversity Core Facility (POSTECH). Analytical HPLC
was performed on Agilent 1100-HPLC Chemstation with an
analytical column ZORBAX C8-monomeric (BU-300, 5 𝜇m,
300 A˚, 4.6 × 250mm).
2.2. Characterization of Synthetic Compounds
(S)-Ethyl-2-(2-(4-isobutylphenyl)propanamido)acetate (1). A
solution of (S)-(+)-ibuprofen (140mg, 0.68mmol), glycine
ethylester hydrochloride (104mg, 0.75mmol), EDC (195mg,
1.02mmol), triethylamine (1.04ml, 0.748mmol), and DMAP
(42mg, 0.34mmol) in DMF (2ml) was stirred at rt under
N2(g). After stirring for 24 h, the solution was treated with
ethylacetate and washed several times with saturated aq.
NaHCO3, water, and brine. The organic phase was dried
over Na2SO4 and concentrated to give the crude product,
which was purified by column chromatography on silica gel
eluting with 1 : 5 EtOAc/hexane to afford (1) (199mg, 99%) as
a colorless liquid.
𝑅𝑓: 0.54 (Hexane : EtOAc = 7 : 3);
1H-NMR (300MHz,
CDCl3, ppm) 𝛿 0.99 (d, J = 6.6Hz, 6H), 1.23 (t, J = 6.9Hz,
3H), 1.51 (d, J = 7.2Hz, 3H), 1.84 (m, 1H), 2.44 (d, J = 7.2Hz,
2H), 3.60 (q, J = 7.2Hz, 1H), 3.94 (dd, J = 5.4Hz, J = 12.6Hz,
2H), 4.15 (q, J = 6.9Hz, 2H), 7.11 (d, J = 8.1Hz, 2H), 7.22 (d, J
= 8.1Hz, 2H); 13C-NMR (75MHz, CDCl3, ppm) 𝛿 13.9, 18.3,
22.2, 30.0, 41.3, 44.9, 46.2, 61.1, 127.2, 129.4, 138.1, 140.5, 169.7,
174.5; MS (FAB) [M + H]+ calcd for C17H25NO3 m/z 292.18,
found 292.20.
(S)-2-(2-(4-Isobutylphenyl)propanamido)acetic acid (2).Com-
pound (1) (195mg, 0.67mmol) and lithiumhydroxide (16mg,
0.67mmol) were added to 6ml solution of THF :H2O (5 : 1)
and stirred at rt for 36 h. Then the reaction mixture was
evaporated in vacuo, extracted with EtOAc, and washed
with saturated 1N HCl, water, and brine. The organic phase
was dried over Na2SO4 and concentrated to give the crude
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product, which was purified by column chromatography on
silica gel elutingwith 1 : 2 EtOAc/hexane to afford (2) (105mg,
60%) as a white solid.
𝑅𝑓: 0.12 (Hexane : EtOAc = 7 : 3); M.p. 87–90
∘C; 1H-NMR
(300Mhz, CDCl3, ppm) 𝛿 0.88 (d, J = 6.6Hz, 6H), 1.49 (d, J
= 7.2Hz, 3H), 1.83 (m, 1H), 2.43 (d, J = 7.2Hz, 2H), 3.62 (q, J =
7.2Hz, 1H), 3.94 (dd, J = 5.4Hz, J = 18.3Hz, 2H), 6.35 (m, 1H,
NH), 7.09 (d, J = 8.1Hz, 2H), 7.18 (d, J = 8.1Hz, 2H);MS (FAB)
[M + H]+ calcd for C15H21NO3 m/z 264.15, found 264.17.
1-O-(N-Cbz-6-aminohexanoyl)-2,3,4,5-tetra-O-(N-{bis-[3-(N󸀠,
N󸀠󸀠-bis-Boc-guanidino)-propyl]}-6-aminohexanoyl)-6-O-d-
sorbitol (4). A column of flash silica gel was packed con-
secutively in hexane with 1% triethylamine and then hexane
with 1% TFA; a sea sand layer was placed in between layers.
Compound (3) (98mg, 0.028mmol) was dissolved in 1%TFA
containing CH2Cl2 and sonicated for several seconds. The
solution was then loaded on the column chromatography
and was eluted with increasing MeOH in CH2Cl2 (15 : 1) to
give compound (4) (66mg, 73%) as a colorless foamy solid.
𝑅𝑓: 0.44 (CH2Cl2:MeOH = 10 : 1);
1H-NMR (300MHz,
CDCl3, ppm) 𝛿 1.22–1.79 (m, 190H), 2.02–2.62 (m, 32H), 3.15–
3.48 (m, 18H), 3.68 (m, 2H), 4.31–4.40 (m, 4H), 4.89–5.07
(m, 2H), 5.08 (s, 2H), 5.10–5.30 (m, 2H), 7.34 (m, 5H), 8.51
(brs, 8H), 11.48 (brs, 8H); 13C-NMR (75MHz, CDCl3, ppm)
𝛿 14.1, 22.7, 24.0, 24.3, 24.8, 25.3, 26.3, 27.1, 28.0, 28.1, 28.3, 28.3,
28.8, 29.3, 29.7, 29.9, 33.9, 35.5, 38.0, 39.0, 40.9, 49.9, 51.3, 51.5,
51.5, 53.1, 63.6, 66.5, 79.2, 79.7, 80.0, 80.5, 83.0, 83.3, 83.7, 84.5,
84.9, 85.1, 93.4, 114.5, 118.3, 122.6, 127.2, 127.9, 128.0, 128.5, 128.7,
136.7, 142.1, 143.3, 148.7, 153.0, 153.1, 155.8, 156.1, 156.7, 163.5,
171.8, 172.5, 172.7, 172.8, 173.1, 181.6, 185.0, 185.2.
1-O-(2-Aminoacetoxy-ibuprofen)-2,3,4,5-tetra-O-(N-{bis-[3-
(N󸀠,N󸀠󸀠-bis-Boc-guanidino)-propyl]}-6-aminohexanoyl)-6-O-
(N-Cbz-6-aminohexanoyl)-d-sorbitol (5). To a solution of
(4) (90mg, 0.027mmol) in DMF (2ml) at rt were added (2)
(10.7mg, 0.041mmol), EDC (11mg, 0.054mmol), and DMAP
(2mg, 0.016mmol). After stirring for 48 h under N2(g),
The solution was concentrated under reduced pressure. The
residuewas dissolved inEtOAc andwashed several timeswith
saturated aq. NaHCO3, water, and brine. The organic phase
was dried over Na2SO4 and concentrated to give the crude
product, which was purified by column chromatography
on silica gel eluting with 1 : 20 MeOH/CH2Cl2 to afford (5)
(50mg, 52%) as a white foamy solid.
𝑅𝑓: 0.46 (CH2Cl2:MeOH = 10 : 1);
1H-NMR (300MHz,
CDCl3, ppm) 𝛿 0.88–0.90 (m, 6H), 1.25–1.69 (m, 193H), 2.32–
2.45 (m, 32H), 3.08–3.50 (m, 18H), 3.61–3.71 (m, 2H), 3.97–
4.29 (m, 4H), 4.85–5.12 (m, 4H), 5.02 (s, 2H), 5.33 (m, 1H),
7.09–7.12 (m, 2H), 7.22–7.27 (m, 2H), 7.33 (m, 5H), 8.49–8.57
(m, 8H), 11.40 (m, 8H); 13C-NMR (75MHz, CDCl3, ppm) 𝛿
14.1, 18.6, 22.4, 22.7, 24.0, 24.3, 24.6, 26.3, 28.0, 28.1, 28.3, 28.3,
29.4, 29.7, 30.2, 31.9, 38.0, 39.0, 45.1, 49.9, 53.2, 66.5, 79.2, 79.8,
83.0, 83.7, 118.3, 122.6, 127.2, 127.4, 127.7, 127.9, 128.0, 128.5, 128.7,
129.5, 129.7, 136.7, 138.7, 140.5, 143.3, 153.0, 153.1, 156.2, 156.5,
156.8, 162.9, 163.5, 170.3, 172.6, 172.8, 174.3, 181.6.
1-O-(2-Aminoacetoxy-ibuprofen)-2,3,4,5-tetra-O-(N-{bis-[3-
(N󸀠,N󸀠󸀠-bis-Boc-guanidino)-propyl]}-6-aminohexanoyl)-6-O-d-
sorbitol (6). A solution of (5) (45mg, 0.013mmol) in a mixed
solvent (CH2Cl2 :MeOH = 1 : 9, 10ml) was hydrogenated
(50 psi) at rt over 10% Pd/C (25mg). After 12 h, the catalyst
was filtered and the filtrate was evaporated to give the amino
compound (6) (38mg, 88%) as a colorless sticky liquid.
1H-NMR (300 MHz, CDCl3, ppm) 𝛿 0.88–0.90 (m, 6H),
1.25–1.77 (m, 193H), 2.25–2.45 (m, 32H), 3.09–3.50 (m, 18H),
3.61–3.71 (m, 2H), 4.01–4.29 (m, 4H), 4.85–5.12 (m, 4H), 5.33
(m, 1H), 7.09–7.12 (m, 2H), 7.22–7.27 (m, 2H), 8.56 (brs, 8H),
11.39 (brs, 8H).
1-O-(2-Aminoacetoxy-ibuprofen)-2,3,4,5-tetra-O-(N-{bis-[3-
(N󸀠,N󸀠󸀠-bis-Boc-guanidino)-propyl]}-6-aminohexanoyl)-6-O-
[6-(fluoresceinyl-5-thioureido)-hexanoyl]-d-sorbitol (7). To
a solution of amino compound (6) (38mg, 0.011mmol) in
a mixed solvent THF and absolute ethanol (3ml, 1 : 2) were
added fluorescein-5-isothiocyanate (6.5mg, 0.017mmol)
and triethylamine (4.6 𝜇l, 0.033mmol). The reaction mixture
was stirred for 36 h at rt in dark and then concentrated in
vacuo. The crude product was purified on silica gel eluting
with 1 : 20 MeOH/CH2Cl2 to afford (7) (25mg, 60%) as a
light greenish-yellow sticky solid.
𝑅𝑓: 0.42 (CH2Cl2 :MeOH = 10 : 1);
1H-NMR (300MHz,
CDCl3, ppm) 𝛿 0.88–0.90 (m, 6H), 1.25–1.85 (m, 193H), 2.31–
2.44 (m, 32H), 3.09–3.48 (m, 18H), 3.66 (m, 2H), 𝛿 4.15–4.29
(m, 4H), 4.88–5.07 (m, 4H), 5.34 (m, 1H), 6.51–7.32 (m, 11H),
7.73 (m, 1H), 8.04 (m, 1H), 8.57 (brs, 8H), 11.39 (brs, 8H).
1-O-(2-Aminoacetoxy-ibuprofen)-2,3,4,5-tetra-O-[N-{bis-(3-
guanidinopropyl)}-6-aminohexanoyl]-6-O-[6-(fluoresceinyl-
5-thioureido)-hexanoyl]-d-sorbitol⋅8HCl (8). To a solution
of (7) (20mg, 0.005mmol) in EtOAc (1ml) at rt was added
the HCl(g) saturated solution of EtOAc (5ml). After stirring
for 24 h, the solution was concentrated, and the residue was
washed with a mixture of diethyl ether and MeOH (20 : 1)
to remove less polar impurities. The residue was dried and
purified sequentially byMPLC on reverse phase C-8 silica gel
(H2O/CH3CN= 1 : 1 to 1 : 2) and RP-HPLC (GRACEVYDAC,
C18, 2.0mlmin−1, 10% to 60% CH3CN in H2O, 220 nm).The
purified product was lyophilized to give (8) (7.6mg, 58%) as
a light greenish-yellow sticky solid (HCl salt).
Analytical HPLC (ZORBAX SB-C8): tR = 2.1min (flow
rate: 1 cm3min−1; UV = 220 nm; isocratic CH3CN :H2O
= 30 : 70), purity 99+%; UV (H2O): 𝜆max 492 nm, 𝜀 =
18,333 cm−1M−1); 1H-NMR (300MHz, MeOD, ppm) 𝛿 0.89–
0.91 (m, 6H), 1.01–1.80 (m, 45H), 2.00–2.09 (m, 16H), 2.38–
2.43 (m, 16H), 3.29–3.32 (m, 16H, partially overlapped with
MeOD peak), 3.48–3.88 (m, 6H), 4.03–4.55 (m, 9H), 5.00–
5.41 (m, 2H), 6.66–6.78 (m, 6H), 7.09–7.34 (m, 4H), 7.70 (m,
1H), 7.80 (m, 1H), 8.06 (m, 1H); MALDI-TOF-MS [M + Na]+
calcd for C104H171N31O18SNam/z 2198.30, found 2198.96.
Fluoresceinyl (S)-2-(2-(4-Isobutylphenyl)propanamido)-ace-
tate (9). A solution of (S)-(+)-ibuprofen (70mg, 0.34mmol),
fluorescein amine (129mg, 0.37mmol), EDC (97mg,
0.51mmol), and DMAP (21mg, 0.17mmol) in DMF (2ml)
was stirred at rt under N2(g). After 24 h, the solution was
treated with EtOAc and washed several times with saturated
aq. NaHCO3, water, and brine. The organic phase was dried
and concentrated to give the crude product, which was
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purified by column chromatography on silica gel eluting
with 1 : 20MeOH/CH2Cl2 to afford (9) (140mg, 77%) as a
yellowish sticky liquid.
𝑅𝑓: 0.54 (CH2Cl2 :MeOH = 10 : 1);
1H-NMR (300MHz,
CDCl3, ppm) 𝛿 0.90 (d, J = 6.6Hz, 6H), 1.59 (d, J = 7.2Hz,
3H), 1.85 (m, 1H), 2.46 (d, J = 7.2Hz, 2H), 6.54–6.72 (m,
4H), 6.78–6.95 (m, 4H), 7.11 (m, 3H), 7.28 (m, 2H); 13C-NMR
(75MHz, CDCl3, ppm) 𝛿 18.7, 22.7, 30.5, 31.8, 36.9, 45.3, 45.5,
103.2, 108.7, 110.3, 110.3, 110.8, 113.0, 117.2, 117.2, 117.7, 122.7, 124.9,
127.5, 128.3, 129.3, 129.4, 129.9, 137.2, 141.2, 142.9, 148.7, 152.2,
152.3, 152.6, 159.5, 163.1, 170.3, 173.2;MS (FAB) [M+H]+ calcd
for C33H29NO6 m/z 535.20, found 535.19.
2.3. Biological Assays
2.3.1. Materials. High glucose Dulbecco’s modified Eagle’s
medium (DMEM), Dulbecco’s phosphate buffered saline
(PBS, pH 7.4), fetal bovine serum (FBS), and trypsin/EDTA
were obtained from Invitrogen. Milli-Q purified water
(18.2MΩ) was used to prepare all of the solutions.
2.3.2. Cell Culture. HeLa cells were incubated at 37∘C in a
humidified 5% CO2 containing air environment in DMEM
and 10% (v/v) FBS with penicillin. The subculture was
performed every 2-3 days until the cells were grown to
subconfluence.
2.3.3. Cellular Uptake Experiment. HeLa cells (1 × 105 cells
per well) were seeded into a 35mm cover glass bottomed
dish (SPL Ltd., Republic of Korea) and incubated for 24 h.
After removing the media, HeLa cells were washed with cold
PBS (×1). The cells were incubated for 30min at 37∘C in 3ml
of DMEM containing 10 𝜇M of compound (8) or (9). After
incubation, the cell media were removed and HeLa cells were
washed five times with cold PBS, replaced with cold PBS,
and then observed directly on the cover glass bottom dish.
Confocal laser scanning microscope was performed by using
an Olympus Fluoview FV1000 equipped with an NA 1.30,
40x, planApo, oil immersion lens. Fluorescence of FITC was
analyzed and collected using the excitation bands at 488 nm
and emission bands from 500 to 530 nm. All the experiment
was performed in triplicate.
2.3.4. Mouse Tissue Biodistribution. Compound (8) or (9)
(94.6mg kg−1)was dissolved in sterile distilledwater (500𝜇L)
and each solution was injected intraperitoneally (ip) into
eight-week-old mice (C57BL/6, 22 g). After 20min, the
administered mice were perfused with paraformaldehyde
(4%) in PBS (pH 7.4), and the major organs (brain, heart,
lung, kidney, spleen, and liver) were incubated overnight in a
solution of sucrose (0.5M) in PBS. Placed in cryoprotectant,
they were cut into 15 𝜇m sections with a cryostat and trans-
ferred to coated glass slides. After drying, each section was
washed with PBS, treated with Triton X-100 (0.3%) for 15min
at rt, and then analyzedwith anAxioplan2 fluorescence imag-
ing microscope. As a control, triple distilled water (500𝜇L)
was also injected into the mouse and treated in the same
process. Green fluorescence from FITC labeled compounds
in each tissue was compared with autofluorescence from
the control. All mouse experiments were performed in the
POSTECH animal facility in compliance with the relevant
laws and institutional guidelines.
2.3.5. Plasma Stability Test. A homogenous solution of (8)
in distilled water (500𝜇gml−1) was prepared for the deter-
mination of plasma stability. Aliquots were withdrawn and
added into plasma (from human, Sigma, USA), resulting in
a final concentration of 50 𝜇gml−1, which was vortexed and
incubated at 37∘C for predetermined times (0, 3, 6, 9, 12, 15, 18,
21, and 24 h). Then aliquots of plasma solution (200𝜇l) were
withdrawn to be mixed with 1ml MeOH to prevent further
hydrolysis of (8). To the solution was added biotin (internal
standard) in distilled water (100 𝜇l, 5 𝜇gml−1) followed by
centrifugation at 2000 rpm for 10min. The supernatant was
collected and dried under air flow. The residue was dissolved
in distilled water (2ml) and centrifuged at 2000 rpm for
10min. The obtained supernatant was analyzed using HPLC
by the following method.
2.3.6. HPLC Analysis. As described earlier, a clear super-
natant was obtained, and 10 𝜇l was injected into HPLC
system. The UV detector was operated at 260 nm, and
the flow rate used was 1.0mlmin−1 for 10–15min running
time. The isocratic mobile phase system was composed of
MeOH/H2O (30/70), and the column ovenwasmaintained at
37∘Cwith an analytical C18-column (Agilent, ZORBAX, 4.6×
250mm, 5 𝜇m). At each interval, HPLC chromatograms were
obtained and the remained percentage of (8) was calculated
by subtracting the released ibuprofen concentration, based on
area under curve, from the sum of initial concentration of (8)
and internal standard.
3. Results and Discussion
3.1. Synthesis of Ibuprofen Conjugate. Since the S-(+) enan-
tiomer of ibuprofen (dexibuprofen) is more active in inhibit-
ing the COX enzymes, the S-(+) isomer was used as a
model drug of NSAID. Attempting to increase the efficiency
of the coupling of ibuprofen into the sterically crowded
scaffold (sorbitol), we synthesized an ibuprofen derivative
using glycine as a spacer (Scheme 1). S-(+)-Ibuprofenwas first
coupled with ethylglycinate to form compound (1) which was
further treated with lithium hydroxide to give the compound
(2) in accordance with the reported procedure [26]. The acid
(2) was used as a precursor of ibuprofen conjugate.
From our previous study, we had observed that the
branched side chains with bis-guanidine moiety at the ter-
minal and five-carbon units in the 𝜔-amino acid chain give
better efficiency toward cell penetration than other versions
of derivatives [22]. Therefore, we synthesized the ibuprofen
attached sorbitol derivative with five-carbon attached side
chains (Scheme 2). To synthesize compound (3), we started
from the commercially available d-glucose. Following several
steps in the reported procedure [22], d-glucose was reduced
to acylated sorbitol, which was consecutively coupled with
Cbz-protected aminocaproic acid to form compound (3). To
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Scheme 1: (a) Glycine ethylester⋅HCl, EDC, DMAP, DMF, and Et3N, rt, 24 h, 99%; (b) LiOH and THF-H2O (5 : 1), rt, 36 h, 60%.
remove the trityl group selectively in (3) in the presence
of eight Boc groups, gradients of CH2Cl2/MeOH mixture
were eluted through a flash SiO2 column packed in hexane
containing 1% TFA at the top and hexane containing 1% Et3N
on the bottom [27]. As a result, compound (4)was obtained in
73% yield after column chromatography.The hydroxyl group
of (4) was coupled with the ibuprofen derivative (2) in the
presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
(EDC) and 4-dimethylaminopyridine (DMAP) in DMF to
afford the conjugate (5) in moderate yield. The conjugation
was covalently formed via an ester bond, which can be easily
hydrolyzed to release ibuprofen after reaching the target.
Deprotection of N-Cbz group in the compound (5) was
performed using 10%Pd/C and hydrogen gas under 50 psi
to give the amino compound (6), which did not require
further purification. In order to attach a fluorescent probe, the
compound (6) was treated with fluorescein-5-isothiocyanate
(FITC) and Et3N in a mixed solvent THF/ethanol to give
the compound (7) in moderate yield. Finally, the compound
(7) was treated with ethylacetate saturated with HCl (gas)
to remove all the Boc groups of the guanidine moieties to
yield compound (8) as hydrochloride salts. The resulting salt
(8) was purified by medium pressure liquid chromatography
(MPLC) using a reverse-phase (C8) column. In order to com-
pare the delivery efficiency between the compound (8) and
the blank compound (i.e., without sorbitol-based molecular
transporter), we had synthesized the compound (9) by EDC
coupling strategy at room temperature (Scheme 3). Then (9)
was further purified by column chromatography on silica gel.
3.2. Cellular Uptake Study of the Ibuprofen Conjugate. In
order to check whether the synthetic conjugate (8) can cross
the cell membrane and translocate itself inside cells, we
investigated its intracellular delivery properties by means of
confocal microscope (Olympus Fluoview FV1000, NA 1.30,
40x). The conjugate (8) (10 𝜇M in PBS) was added to the
media of live HeLa cells and was incubated together at 37∘C
for 30min. Then the cells were washed with cold PBS twice
and the cellular internalization of the compound and its
localization could be examined by the fluorescence of the
labeled fluorescein. Figure 2 shows strong green fluorescence
appearing mainly in the cytoplasm, and this indicates (8)
can cross the cellular membrane and diffuse efficiently in the
cytoplasm. However, unlike the ibuprofen conjugate, where
ibuprofen conjugated only with FITC (9) was incubated in
HeLa cells in the samemanner, no fluorescence was observed
inside the cells. This result confirms the guanidine moieties
in the conjugate structure are completely essential in deliv-
ering ibuprofen into cells. Although the exact mechanism of
cellular uptake mediated by guanidine is very complicated
and sometimes remains controversial, according to recent
publications it is assumed that, at the initial stage of cell
uptake, a strong association takes place between the cationic
guanidine and anionic cell membrane constituents such as
sulfate, carboxylate, and phosphate groups [28, 29].
3.3. Mouse Tissue Distribution Experiment. The possibility of
BBB penetration of the conjugate (8) was tested by studying
the tissue distribution in mice. The conjugate (8) (HCl salt,
94.4mg kg−1) was dissolved in sterile distilled water and
the solution was injected intraperitoneally into an 8-week-
old mouse (C57BL/6). After 20min, the injected mouse was
transcardially perfused with paraformaldehyde in phosphate
buffered saline solution (pH 7.4). The major organs such as
brain, heart, lung, kidney, spleen, and liver were incubated
overnight in a solution of sucrose (0.5M) in PBS. Placed
in cryoprotectant, the tissues were cut into 15 𝜇m sections
with a cryostat and transferred to coated glass slides. After
drying, sections were treated with Triton X-100 for 15min
and then analyzed with fluorescence microscope (Figure 3).
As a control study, only PBS was injected to another mouse.
In the previous study, the sorbitol G8 transporter showed
preferred distribution patterns to heart and brain than to
other tissues [22]. Conjugate (8) shows preferred locations to
be in the brain and the kidney, while much less distributions
were observed in the spleen and the liver and none in the
heart and the lung.This shows the conjugate can readily cross
theBBB andpenetrate into themouse brain. Similarly, (9)was
used for the experiment with the same procedure but showed
no distribution in the brain. We presume that the guanidine-
rich region of (8) forms noncovalent bonds with brain cell
surface units through charge pairing and hydrogen bonding.
After this interaction, (8) might cross the BBB by endocytosis
[28, 30].
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Figure 2: Cellular uptake of (8) and (9) in live HeLa cells. (a) fluorescence image, (b) DIC (differential interference contrast) image, (c) merge
image of (a) and (b) from (8) (ibuprofen conjugate) treated cells, (d) fluorescence image, and (e) DIC image from (9) (control) treated cells.
Scale bar: 20 𝜇m.
3.4. In Vitro Plasma Stability Test. To determine the stability
of the ibuprofen conjugate, (8) was incubated in the presence
of human plasma. Initially, ibuprofen, biotin as internal
standard, blank plasma, and (8) were analyzed, respectively,
by HPLC at 260 nm to determine each retention time (min):
ibuprofen: 3.9, biotin: 3.1, blank plasma: 4.0 and 5.2, and (8):
7.8.
Compound (8) was dissolved in distilled water (500𝜇g
ml−1), and then aliquots were mixed with plasma to be
a concentration of 20𝜇gml−1. During incubating solution
at 37∘C, aliquots (200 𝜇l) were withdrawn periodically and
mixed with MeOH (1ml) and biotin (100 𝜇l, 5 𝜇gml−1) as an
internal standard. After centrifugation, the supernatant was
collected and 10 𝜇l of the solution was injected for RP-HPLC
equipped with a C18-analytical column. Samples detecting at
260 nm showed a slight shift of retention time of each species,
and particularly the released ibuprofen was identified by the
peak with retention time at 3.96min (Figure 4(a)). After 3 h
incubation, compound (8) underwent hydrolysis around 5%
with respect to the initial time (0 h). With the increase of
time, however, the remaining percentage decreased slowly
∼8% in next 21 h incubation time (Figure 4(b)).This indicates
(8) has sufficient stability and long half life time in plasma,
and the compound could gain higher possibility to reach the
BBB.
4. Conclusions
In conclusion, ibuprofen conjugate (8) was prepared using
a sorbitol-based G8 molecular carrier and showed good
distribution toward mouse brain. Although there is no
cure or protecting agent for neurodegenerative disease yet,
NSAIDs are being reported to give beneficial neuroprotection
effects. To deliver a drug into brain in optimal dose and to
minimize side effects, an efficient and specific delivery system
overcoming the BBB is highly required. We have succeeded
in delivering ibuprofen conjugate to mouse brain, and our
prodrug methodology is applicable to virtually all other
NSAIDs, such as flurbiprofen. Further studies are in progress
to demonstrate the delivery of other popular NSAIDs to the
brain and the central nervous system.
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